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Abstract
A detailed study was performed to compare the in vivo ileal digestibility andmodulatory effects in fecal microbiota of novel
galacto-oligosaccharides (GOS) derived from lactulose [GOS-Lu; degree of polymerization (DP)$2, 14.0% trisaccharides]
and commercial GOS derived from lactose (GOS-La; DP $3, 35.1% trisaccharides) in growing rats (5 wk old). Rats were
fed either a control diet or diets containing 1% (wt:wt) of GOS-Lu or GOS-La for 14 d. Quantitative analysis of
carbohydrates from dietary and ileal samples demonstrated that the trisaccharide fraction of GOS-Lu was significantly
more resistant to gut digestion than that from GOS-La, as indicated by their ileal digestibility rates of 12.56 2.6% and 52.9
6 2.7%, respectively, whereas the disaccharide fraction of GOS-Lu was fully resistant to the extreme environment of the
upper digestive tract. The low ileal digestibility of GOS-Lu was due to the great resistance of galactosyl-fructoses to
mammalian digestive enzymes, highlighting the key role played by the monomer type and linkage involved in the
oligosaccharide chain. The partial digestion of GOS-La trisaccharides showed that glycosidic linkages (1/6) and (1/2)
between galactose and glucose monomers were significantly more resistant to in vivo gastrointestinal digestion than the
linkage (1/4) between galactose units. The absence of GOS-La and GOS-Lu digestion-resistant oligosaccharides in fecal
samples indicated that they were readily fermented within the large intestine, enabling both types of GOS to have a
potential prebiotic function. Indeed, compared with controls, the GOS-Lu group had significantly more bifidobacteria in
fecal samples after 14 d of treatment. The number of Eubacterium rectale also was greater in the GOS-Lu and GOS-La
groups than in controls. These novel data support a direct relationship between patterns of resistance to digestion and
prebiotic properties of GOS. J. Nutr. 142: 1232–1239, 2012.
Introduction
The mammalian intestine harbors a complex microbial ecosystem
consisting of an extraordinary number of resident commensal
bacteria existing in homeostasis with the host (1). These endog-
enous microbiota establish a symbiotic, mutualistic relationship
and affect numerous physiological functions, including nutrition
exchange, control of epithelial cell proliferation/differentiation,
pathogen exclusion, and stimulation of the immune system (2,3).
Currently, there is a growing interest in identifying functional
dietary compounds capable of modulating the composition and
metabolic activities of the intestinal microbiota. These com-
pounds, named prebiotics, were recently redefined as “non-
digestible functional ingredients which are selectively fermented
and allow specific changes, both in the composition and/or
activity of the gastrointestinal microflora that confers benefits
upon host well-being and health” (4). Bifidobacteria and lacto-
bacilli species are among the most relevant ones that are thought
to play an important role in maintaining and promoting a healthy
gut environment (5,6). The major prebiotic oligosaccharides on
the market are fructan inulin, fructo-oligosaccharides, and
galacto-oligosaccharides (GOS)7 (7). GOS are nondigestible
carbohydrates usually comprised of 2–10 molecules of galactose
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and a terminal glucose unit, which are derived primarily from trans-
galactosylation reactions of lactose catalyzed by b-galactosidases
of fungal, bacterial, or yeast origin, to result in oligosaccharides
with different glycosidic linkages and degrees of polymerization
(DP) (8). Recently, the synthesis and detailed chemical character-
ization of novel lactulose-derived GOS (GOS-Lu) was accom-
plished (9–11). GOS-Lu are attracting increasing attention due to
their prospective prebiotic applications, in particular their ability
to promote the in vitro growth of several probiotic strains of
Lactobacillus and Bifidobacterium (12), as also shown for
commercial lactose-derived GOS (GOS-La) (9,13).
To exert their potential prebiotic properties, oligosaccharides
have to resist and survive, at least to some extent, the acidic
environment and enzymatic digestion in the upper digestive tract.
Thus, dietary oligosaccharides that escape digestion by endoge-
nous enzymes and absorption in small intestine become available
to microbial fermentation in the large intestine (14). Although a
number of in vitro and in vivo studies have demonstrated the
potential health benefits of GOS-La, there have been few attempts
to identify and quantify the intestinal survival of GOS-La and
their derivatives (4). Furthermore, the reported results are scarce
and seem to be controversial mainly due to methodological
difficulties (including complex analytical techniques, sample
availability, and experimental models used). As a result, several
authors have claimed that GOS-La could not fully meet the
criterion of resistance to small intestinal digestion that is
necessary to exert prebiotic properties within the large intestine
(4,15,16). By using digestive enzymes from several sources,
Chonan et al. (17) reported differences in digestibility behavior
between disaccharides and trisaccharides of GOS-La, with the
former being more susceptible to digestion. Ohtsuka et al. (18)
showed that only a small amount of 49-galactosyl-lactose, a major
trisaccharide present in GOS-La, was digested by a homogenate
of intestinal mucosa of rats. Additional studies to distinguish the
differential digestibility of components within complex mixtures
of oligosaccharides are clearly necessary.
Data are not available for the recently characterized GOS-Lu
(11) with regard to resistance to gastric acidity, hydrolysis by
mammalian enzymes, and gastrointestinal absorption. The ex-
ploitation of these promising oligosaccharides as prebiotic com-
pounds will depend largely upon their ileal survival rates after
digestion and their further selective fermentation bymicrobiota in
the large intestine. Therefore, the aims of this work were to carry
out a comparative study in vivo regarding the ileal digestibility of
GOS-La and GOS-Lu and to evaluate if their major components
are fermented by themicrobiota to promote the selective growth of
beneficial bacteria in the large intestine of rats.
Materials and Methods
Materials. Analytical standards of lactulose [b-Gal-(1/4)-Fru], lactose
[b-Gal-(1/4)-Glc], sucrose [a-Glc-(1/2)-b-Fru], maltose [a-Glc-(1/
4)-D-Glc], maltotriose [a-Glc-(1/4)-a-Glc-(1/4)-D-Glc], raffinose
[a-Gal-(1/6)-a-Glc-(1/2)-b-Fru], a,a-threhalose [a-Glc-(1/1)-a-
Glc], and b-galactosidase from Aspergillus oryzae, phenyl-b-D-gluco-
side, hexamethyldisilazane, and hydroxylamine hydrochloride were
obtained from Sigma. 1,6-Galactobiose [b-Gal-(1/6)-Gal], 1,4-galac-
tobiose [b-Gal-(1/4)-Gal], and 1,3-galactobiose [Gal-(1/3)-Gal]
were supplied by Dextra Laboratories. 69-Galactosyl-lactose [b-Gal-
(1/6)-Gal-b-(1/4)-Glc] was a gift from Professor Nieves Corzo from
CIAL-CSIC (Madrid, Spain).
Synthesis and preparation of GOS. An industrially available GOS
mixture derived from lactose (GOS-La) was used in this study. To
remove the mono- and disaccharides, the mixture was fractionated using
size-exclusion chromatography (19). Briefly, 80 mL of GOS-La (25% wt:v)
was injected in a Bio-Gel P2 (Bio-Rad) column (903 5 cm) using water as
the mobile phase at a flow of 1.5 mL/min. The DP of collected fractions
was determined by electrospray ionization-MS at positive mode. Fractions
with DP $3 were pooled and freeze-dried to be used in the in vivo
experiments. The trisaccharide content of GOS-La was determined by
hydrophilic interaction chromatography coupled to MS (20). Then 20 mL
of sample was injected onto an ethylene-bridged hybrid amide column
(150mm3 4.6 mm; 3.5mm; XBridge). The elutionwas performed using a
linear gradient of acetonitrile:MilliQ water, both having 0.1% NH4OH,
from 80:20 (v:v) to 50:50 (v:v) for 31 min. The separation and detection
were carried out using an Agilent 1200 series HPLC system (Hewlett-
Packard) coupled to a quadrupole HP-1100 mass detector (Hewlett-
Packard) provided with electrospray ionization and used in positive mode.
The trisaccharide fraction was 35.1% of the total purified GOS-La.
Enzymatic synthesis of GOS derived from lactulose (GOS-Lu) was
carried out via the hydrolysis and transgalactosylation of the prebiotic
carbohydrate lactulose (Duphalac, Solvay Pharmaceuticals) by using a
b-galactosidase from Aspergillus oryzae and following the procedure
described by Clemente et al. (21). The GOS mixture was treated with
activated charcoal to remove the monosaccharides fraction (22). A
detailed characterization of GOS-Lu, with di- and trisaccharides as 78
and 14% of total carbohydrates, respectively, was recently reported (11).
Rats and diets. Male weaned Wistar rats (Charles River Laborato-
ries), matched by weight (406 5 g; 4 wk old), were individually housed
in metabolism cages throughout the experiment under controlled
conditions of temperature (258C), moisture (50%), and lighting (12-h
cycles). Rats were fed a diet (AIN-93G, Testdiet) formulated for use
during growth based on corn starch (40%), casein (20%), maltodex-
trin (13.2%), sucrose (10%), and soybean oil (7%) as the main dietary
ingredients (23). A 6-d preexperimental adaptation was followed by a
14-d experimental period. At the end of the adaptation period, rats had
a mean weight of 756 5 g. The 36 rats were then randomly assigned to
3 dietary groups of 12 and consumed food and water ad libitum. Diets
were AIN-93G (control group), AIN-93G plus 1% (wt:wt) GOS-Lu
(GOS-Lu group), and AIN-93G plus 1% (w:w) GOS-La (GOS-La
group). Cr2O3 was included (2 g × kg
21) in all diets as an indigestible
marker (24). Fresh fecal samples from rats subjected to the same dietary
treatment were collected weekly (d 0, 7, and 14), pooled by collected day
(equal weights from 4 rats/pool) in sterile flasks, and frozen prior to
storage at –808C for carbohydrate and microbiological analysis (see
below).
All the experimental protocols were reviewed and approved by the
Institutional Animal Care and Use Committee of the Spanish Council for
Scientific Research, and the rats were cared for in accordance with the
Spanish Ministry of Agriculture guidelines (RD 1201/2005).
Ileal sample collection. At the end of the dietary intervention period
(14 d), rats were deprived of food overnight, fed 4 g at timed intervals so
that time elapsed between feeding and sacrifice was the same for all rats
(2 h). Rats were killed under sodium pentobarbital (40mg/kg body weight)
anesthesia. The ileum (last 20 cm of small intestine) was immediately
dissected out and rinsed with sterile distilled water to collect the ileal
content. Intestinal contents of individual rats were immediately frozen,
freeze-dried, and stored at –808C. Stomach, cecum, and colon were also
washed with sterile distilled water and weighed.
Quantitative determination of GOS (di- and trisaccharides) by
GC-MS. Di- and trisaccharides, derived from GOS-La and GOS-Lu,
were identified and quantified in dietary, ileum, and fecal samples by GC-
MS, following sequential derivatization, using oximation and trime-
thylsilylation steps. A solution was prepared by dissolving 50 mg of
sample in 2 mL of 70% (v:v, ethanol:water) at 48C and filtered (0.20 mm)
and 1 mL mixed with 0.25 mL of phenyl-b-D-glucoside (1 g/L), used as
an internal standard, and evaporated under vacuum. Carbohydrates were
derivatized to their corresponding trimethylsilyloximes (TMSO) as previ-
ously reported (25). GC-MS analyses were carried out using an Agilent
Technologies 7890A gas chromatograph (Hewlett-Packard) coupled to a
5975C quadrupole mass detector operating in electronic impact mode at
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70 eVand using helium as the carrier gas (1 mL/min) (25). A 30-m3 0.25-
mm i.d 3 0.25-mm film thickness fused silica column with cross-linked
methyl silicone (Teknokroma) was used. All analyses were carried out in
triplicate.
Identification of TMSO derivatives of carbohydrates was carried out by
comparison of mass spectra and retention indices (IT) with standard
carbohydrates previously derivatized. Earlier data (26,27) were used to
identify carbohydrates not commercially available; such identifications were
considered to be tentative. Carbohydrate quantitative data were obtained
from GC-MS peak areas using the internal standard method; standard
solutions from 0.003 to 1 mg of lactulose, maltose, sacarose, maltotriose,
and raffinose were prepared to calculate the corresponding response factors
relative to internal standard and used to quantify di- and trisaccharides.
Ileal and fecal digestibility. The ileal apparent digestibility (%) of
GOS-Lu and GOS-La was calculated according to the expression: [(Pf/
Cr2O3f) – (Pi/Cr2O3i)]/(Pf/Cr2O3f) 3 100, where Pf and Pi represent the
amount of carbohydrates (mg/100 mg of sample) in feed and ileal
samples, respectively, determined by GC-MS analyses, and Cr2O3f and
Cr2O3i are chromium oxide concentrations (mg/100 mg) in feed and
ileal contents (24). In a similar way, fecal digestibility of the different
compounds at the end of the experimental period (14 d) was also
evaluated. Chromium oxide content was determined in experimental
diets, and ileal and fecal samples following the procedure described by
Fenton and Fenton (28).
DNA extraction from fecal samples. Total DNA was isolated from
freeze-dried fecal samples (40 mg) using the QIAamp DNA stool kit
(Qiagen) and following the manufacturer’s instructions. Eluted DNAwas
treated with RNase (Invitrogen) and DNA concentration spectrophoto-
metrically assessed by using a NanoDrop ND-100 Spectrophotometer
(NanoDrop Technologies). Purified DNA samples were stored at 2808C.
qPCR analysis. qPCR was used to monitor the modulatory effect of
GOS-Lu and GOS-La on the fecal microbiota of rats during 14 d of
treatment. Different microbial groups, including total bacteria, Bacte-
roides, Lactobacilli, Bifidobacteria, Eubacterium rectale/Clostridium
coccoides, and Clostridium leptum, were distinguished and quantified
using qPCR. The 16S rDNA-targeted group-specific primers used in this
study are listed in Supplemental Table 1. qPCR assays were performed
using an iQ5 Cycler Multicolor PCR detection system (BioRad Labo-
ratories). The reaction mixture (25 mL) comprised 12.5 mL of iQ SYBR
Green Supermix (BioRad), 0.75 mL of each of the specific primers (10
mmol/L; Roche Diagnostics), 9 mL of sterile distilled water, and 2 mL of
DNA template. For total bacteria, Bacteroides, Bifidobacteria, and
Lactobacilli group, PCR conditions included a first step at 508C for 2
min, followed by 958C for 10 min for initial denaturation and 40 cycles
at 958C for 15 s and 608C for 1 min for primer annealing and product
elongation. In the case of Eubacterium rectale/Clostridium coccoides
and Clostridium leptum groups, PCR conditions were an initial
denaturation step at 948C for 5 min followed by 40 cycles at 948C for
20 s, 508C for 20 s, and 728C for 1 min. A plasmid standard containing
the target region was generated for each specific primer set using DNA
extracted from pooled fecal samples of rats fed an AIN-93G diet. The
amplified products were cloned using the TOPO TA cloning kit for
Sequencing (Invitrogen) and transformed into Escherichia coli One Shot
Top 10 cells (Invitrogen). Sequences were submitted to the ribosomal
RNA database to confirm the specificity of the primers (29). For
quantification of target DNA copy number, standard curves were
generated using serial 10-fold dilutions of the extracted products by
using at least 6 non-zero standard concentrations per assay (30). The
bacterial concentration in each sample was measured as log10 copy
number by the interpolation of the Ct values obtained by the fecal
samples and the standard calibration curves. Each plate included
triplicate reactions per DNA sample and the appropriate set of
standards.
Selectivity index. To obtain a general quantitative measure of the
prebiotic effect, selectivity index (SI) values were calculated for the
different treatments. The SI represents a comparative relationship
between the growth of “beneficial” bacteria, including bifidobacteria,
lactobacilli, and Eubacterium rectale, and that of the “less desirable”
ones, such as bacteroides and clostridia, in relation to the change in the
total number of bacteria. The equation to estimate the SI values was
adapted from Palframan et al. (31) as follows: [(Bift/Totalt)/(Bif0/Total0)]
+ [(Lactt/Totalt)/(Lact0/Total0)] + [(Erect/Totalt)/(Erec0/Total0)]2
[(Bactt/Totalt)/(Bact0/Total0)] 2 [(Clostt/Totalt)/(Clost0/Total0)],
where Bif, Lact, Erec, Bact, Clost, and Total are the log10 copy number/g
of freeze-dried fecal sample of bifidobacteria, lactobacilli, Eubacterium
rectale/Clostridium coccoides group, bacteroides, Clostridium leptum
subgroup, and total bacteria, respectively, at the time of sampling (7,14
d), all related to their starting levels (0 d).
Statistics. Individual rats were considered the experimental unit. The
effect of dietary treatment on fecal microbiota composition was analyzed
by 2-way repeated-measures ANOVA using the GLM procedure (SPSS
Statistics version 18.0), according to the following model: Yijk = m + ai +
vk + avik + «ijk, where m is the mean, ai is the effect of diet (control,
GOS-Lu, GOS-La), vk is the time (0, 7, 14 d), avik is the interaction
between diet and time, and the term «ijk represents the random error.
Similarly, SI data were analyzed for dietary treatment and time effects.
Given that the time 3 diet interaction was significant, groups at a time
and time points within group were compared using 1-factor ANOVA.
Means that significantly differed were identified using the Minimum
Significant Difference test. Differences were considered significant at P,
0.05.Values in the text are means 6 SD.
Results
Animal performance. There were no differences among the
groups in food intake (14.26 0.1 g/d) or body weight gain (4.76
0.1 g/d) during the 14-d experiment. In addition, dietary treatments
did not significantly affect the relative weight of different organs,
including stomach, small intestine, cecum, and colon, except that
rats fed GOS-La had a lower relative colon weight compared with
those fed control diets (P , 0.05) (data not shown).
Ileal and fecal digestibility of GOS-Lu and GOS-La.
Quantitative evaluation of carbohydrates from dietary and ileal
samples demonstrated that the disaccharide fraction of GOS-Lu,
mostly composed of b-galactobioses and galactosyl-fructoses
(11), was fully resistant to digestion in the small intestine (Table
1). GC-MS profiles of GOS-Lu disaccharides from dietary and
ileal samples of rats were almost identical, with slight differences
in minor chromatographic peaks, which did not match carbo-
hydrates according to their mass spectra and retention times
(Supplemental Fig. 1A). The chromatographic profile of fecal
samples of rats fed GOS-Lu demonstrated the complete fermen-
tation of the disaccharide fraction in the large intestine;
none of the detected chromatographic peaks of fecal samples
showed the typical mass fragmentation patterns of TMSO
derivatives of carbohydrates. Such peaks were also present in
fecal samples of rats fed the control diet (not shown). As a
result of the high levels of digestible lactose present in the
disaccharide fraction, mono- and disaccharides were removed
from the starting GOS-La. Therefore, no data regarding the
resistance of disaccharides from GOS-La to digestion are
reported in this study.
The GOS-Lu trisaccharide fraction exhibited a limited
digestion, as evaluated in ileal samples of treated rats, showing
a digestibility rate of 12.5 6 2.6% (Table 1); in contrast, GOS-
La trisaccharides were clearly susceptible to small intestinal
hydrolysis, having a much higher digestibility rate (52.9 6
2.7%) (Table 2). An exhaustive analysis of their single
chromatographic peaks, obtained by GC-MS, was carried out
as it is described below. The chromatographic profile of dietary
1234 Herna´ndez-Herna´ndez et al.
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GOS-Lu trisaccharides and those found in ileal samples of rats
fed GOS-Lu are shown (Supplemental Fig. 1B). The similarity
of both chromatographic profiles confirms the high resistance
to digestibility of their major components. As previously
reported, the major trisaccharides of GOS-Lu were identified
as Gal-(1/6)-Gal-(1/4)-Fru (69-galactosyl-lactulose) (peaks
15 and 16) and Gal-(1/4)-Gal-(1/1)-Fru (peak 18) (Supple-
mental Fig. 1B) (9,11). In contrast, some individual GOS-La
trisaccharides were completely digested (Supplemental Fig. 2B);
thus, the chromatographic peaks 13, 14, 19, and 22 were not
found in ileal samples of rats fed GOS-La (Table 2; Supple-
mental Fig. 2B). Indeed, such susceptibility to hydrolysis was
clear from the presence of disaccharides in ileal samples of rats
fed GOS-La (Supplemental Fig. 2A), demonstrating that some
oligosaccharides of DP $3 were hydrolyzed. Di- and trisac-
charides of GOS-La reaching the large intestine were fully
fermented, as indicated by the absence of such oligosaccharides
in fecal samples (Supplemental Fig. 2A,B).
Tentative identification of GOS-La trisaccharides and
disaccharides derived from hydrolysis of oligosaccharides
of DP $3. To determine the chemical structure of GOS-La
oligosaccharides digested at the ileum, a tentative identification
of the TMSO trisaccharides and disaccharides formed as a result
of digestion was carried out by GC-MS analyses. The IT of
carbohydrates present in dietary and ileal samples of rats fed
GOS-La are shown (Table 2). The mass spectrum of peak 1 (IT =
2686) showed a ratio of m/z 191:204:217 ions of 1.4:1:1.1,
characteristic of nonreducing sugars with 1/1 glycosidic link-
ages and consistent with Gal-(1/1)-Gal (1,1-galactobiose)
or Gal-(1/1)-Glc (1,1-galactosyl-glucose). Given that 1,1-
galactobiose shows an IT value of 2903 (11), the chromato-
graphic peak was assigned to 1,1-galactosyl-glucose. Peak 2 was
composed of a mixture of 2 disaccharides, Gal-(1/4)-Glc (1,4-
galactosyl-glucose) and Gal-(1/3)-Glc (1,3-galactosyl-glucose).
The former was assigned by comparison with a GOS previously
obtained by using b-galactosidase from Aspergillus aculeatus
(9), whereas the latter was assigned based on the presence of
relatively highly abundant m/z 205, 244, and 307 ions. Such a
fragmentation pattern is characteristic of the 1/3 glycosidic
linkage and similar to that of the Gal-(1/3)-Gal (1,3-
galactosyl-galactose) standard but with different IT (2699 and
2932, respectively), hampering its tentative identification. Peak 3
showed the typical fragmentation pattern of TMSO carbohy-
drates; however, it could not be identified by its mass spectrum
and retention index. Peak 4 was composed of a mixture of Gal-
(1/4)-Gal (1,4-galactosyl-galactose), identified by comparison
with its corresponding commercial standard, and Gal-(1/4)-
Glc (1,4-galactosyl-glucose, isomer Z), identified in a similar
way to its corresponding E isomer. Similarly, peak 5 was
composed of a mixture of the second peak of Gal-(1/3)-Glc
(1,3-galactosyl-glucose, isomer Z) and an unknown disaccha-
ride. Peaks 6 and 7 were identified as Gal-(1/2)-Glc (1,2-
galactosyl-glucose), isomers E and Z, respectively, by the
presence of the m/z 319 ion with a high abundance, which is
characteristic of 1/2 glycosidic linkages and that corresponds
to the loss of a TMSOH group from the C3-C6 chain of an
hexose group. Peaks 8 and 9 were characterized by a high
intensity ion of m/z 422 corresponding to C1-C4 of the oxime
chain, typical of 1/6 glycosidic linkages, and identified as Gal-
(1/6)-Glc (1,6-galactosyl-glucose) isomers due to a difference
in the IT between these peaks and the corresponding Gal-(1/6)-
Gal (1,6-galactosyl-galactose) standards.
Up to 17 chromatographic peaks corresponding to GOS-La
trisaccharides were detected. Peak 10 had a ratio of ions
191:204:217, typical of 1/1 glycosidic linkages. Peak 16 was
identified as Gal-(1/4)-Gal-(1/4)-Glc (49-galactosyl-lactose)
by comparison with the most abundant trisaccharide of Vivinal-
GOS (26) and supported by previous data reported by Cardelle-
Cobas et al. (13). In peak 17, coelution of 2 compounds occurred,
with the first one being identified as Gal-(1/6)-Gal-(1/4)-Glc
(69-galactosyl-lactose) by comparison with the compound previ-
ously isolated and identified by NMR (10), and the second one
identified as Gal-(1/4)-Gal-(1/2)-Glc 1 by its characteristicm/
z 319 ion and by comparison with that previously identified in
Vivinal-GOS by NMR (26). Peak 20 was composed of 2
compounds, Gal-(1/4)-Gal-(1/2)-Glc 2 and Gal-(1/6)-Gal-
(1/2)-Glc 1, identified in a similar way as the previous peak.
Peak 18 corresponded to the isomers of 49-galactosyl-lactose and
coeluted with another unknown carbohydrate. Peak 23 was
identified as Gal-(1/6)-Gal-(1/6)-Glc by the presence of the
ion at m/z 422 and by comparison with 69-galactosyl-galactose
(13); although the mass spectrum was similar, the retention index
was different due to the presence of a terminal galactose unit
instead of a glucose molecule. Unfortunately, it was not possible
to determine the chemical structure of some GOS-La trisaccha-
rides having low ileal digestibility (peaks 11, 12, 15, 24, 25, and
26) (Table 2) due to the absence of diagnostic ions in the mass
spectra, which, however, were typical of TMSO carbohydrates.
Effect of GOS on fecal microbiota composition. In all
treatments, including the control group, bifidobacteria populations
TABLE 1 Ileal digestibility, IT, and tentative structural identification
of GOS (di- and trisaccharides) of GOS-Lu1
Peak
number2 Disaccharides IT Ileal digestibility2 (%)
Total 0.0
1+2 Gal-(1/4)-Fru (lactulose) 2878–2887
3 Gal-(1/1)-Gal + Gal-(1/4)-Gal E 2903
4 Gal-(1/5)-Fru 1 2915
5a Gal-(1/3)-Gal E + Gal-(1/2)-Gal E 2932
5b Gal-(1/5)-Fru 2 2937
6 Gal-(1/4)-Gal Z + unknown 2959
7 Gal-(1/3)-Gal Z – Gal-(1/2)-Gal Z 2979
8 Gal-(1/6)-Fru 1 3003
9 Gal-(1/6)-Fru 2 3012
10 Gal-(1/1)-Fru 1 3029
11a Gal-(1/6)-Gal E 3046
11b Gal-(1/1)-Fru 2 3049
12 Gal-(1/6)-Gal Z 3094
Peak
number2 Trisaccharides IT Ileal digestibility2 (%)
Total 12.5 6 2.6
13 Unknown 3785
14 Unknown 3794
15 Gal-(1/6)-Gal-(1/4)-Fru 1 3809
16 Gal-(1/6)-Gal-(1/4)-Fru 2 3826
17 Unknown 3835
18 Gal-(1/4)-Gal-(1/1)-Fru 3841
1 Data are mean 6 SD, n = 3 (pools of samples from 4 rats), calculated as ileal
digestibility of the whole fraction of di- or trisaccharides. Fru, fructose; Gal, galactose;
GOS, galacto-oligosaccharide; GOS-Lu, lactulose-derived galacto-oligosaccharide; IT,
retention indices.
2 Labeled peaks are described in Supplemental Figure 1.
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from fecal samples increased throughout the experimental period
(0–14 d). By d 14, the bifidogenic effect was significantly greater in
rats fed GOS-Lu than in those fed GOS-La (Table 3). The GOS-La
group had significantly more lactobacilli in fecal samples than
control or GOS-Lu groups. The number of Eubacterium rectale/
Clostridium coccoides was greater in the GOS-Lu and GOS-La
groups than in controls. At d 7, the SI suggested that there was no
prebiotic effect of GOS-Lu or GOS-La, because that in the GOS-
La group was significantly less than in the control group and that
of the GOS-Lu group did not differ (Fig. 1). The SI increased from
TABLE 2 Ileal digestibility, IT, and tentative structural identification of GOS (di- and trisaccharides) of
GOS-La1
Peak number2 Disaccharides3 IT
1 Gal-(1/1)-Gal or Gal-(1/1)-Glc 2685
2 Gal-(1/4)-Glc E + Gal-(1/3)-Glc E 2699
3 Unknown 2701
4 Gal-(1/4)-Glc Z+ Gal-(1/4)-Gal E 2709
5 Gal-(1/3)-Glc Z + unk 2727
6 Gal-(1/2)-Glc E 2736
7 Gal-(1/2)-Glc Z 2765
8 Gal-(1/6)-Glc E 2824
9 Gal-(1/6)-Glc Z 2868
Peak number2 Trisaccharides
Individual ileal
digestibility (%) Ileal digestibility4 (%)
Total 52.9 6 2.7
10 (1/1)5 3661 6.0 6 1.2
11 Unknown 3675 47.7 6 2.6
12 Unknown 3711 22.6 6 1.8
13 Unknown 3723 99.5 6 2.9
14 Unknown 3755 100.0 6 0.0
15 Unknown 3766 30.2 6 3.3
16 Gal-(1/4)-Gal-(1/4)-Glc E 3775 29.5 6 4.8
17 Gal-(1/6)-Gal-(1/4)-Glc E + Gal-(1/4)-Gal-(1/2)-Glc 3794 77.0 6 6.6
18 Gal-(1/4)-Gal-(1/4)-Glc Z + unk 3801 77.9 6 4.6
19 Unknown 3811 100.0 6 0.0
20 Gal-(1/6)-Gal-(1/2)-Glc 1 + Gal-(1/4)-Gal-(1/2)-Glc 2 3826 0.0 6 0.0
21 Unknown 3862 54.1 6 1.5
22 Unknown 3880 100.0 6 0.0
23 Gal-(1/6)-Gal-(1/6)-Glc 1 3889 81.3 6 3.6
24 Unknown 3963 25.3 6 8.6
25 Unknown 3997 30.4 6 3.5
26 Unknown 4012 29.7 6 1.9
1 Data are mean 6 SD, n = 3 (pools of samples from 4 rats). Gal, galactose; Glc, glucose; GOS, galacto-oligosaccharide; GOS-La, lactose-
derived galacto-oligosaccharide; IT, retention indices.
2 Labeled peaks are described in Supplemental Fig. 2.
3 Disaccharides were not present in GOS-La diet.
4 Calculated as ileal digestibility of the whole fraction of trisaccharides.
5 Nonidentified monomers.
TABLE 3 Microbiota composition in fecal samples obtained from growing rats fed a control, GOS-Lu, or GOS-La diet on d 0, 7,
and 141
Diets Time P value2
Bacterial groups Control GOS- Lu GOS- La 0 7 14 Pooled SEM Diets Time Interaction
log10 copy number/g of freeze-dried fecal sample
All bacteria 10.5a 10.7b 10.8b 10.6a 10.6a 10.9b 0.007 ,0.001 ,0.001 NS3
Bacteroides 10.6a 10.7b 10.9c 10.7b 10.6a 10.8c 0.007 ,0.001 ,0.001 NS
Bifidobacteria 9.82a 10.5c 10.1b 9.68a 10.1b 10.7c 0.024 ,0.001 ,0.001 NS
Lactobacilli 9.64a 9.78b 10.1c 9.52a 9.77b 10.2c 0.006 ,0.001 ,0.001 NS
Eubacterium rectale/Clostridium coccoides group 9.47a 10.1b 10.2b 9.59a 9.83b 10.2c 0.019 ,0.001 ,0.001 NS
Clostrodium leptum subgroup 9.33a 9.48b 9.62c 9.57c 9.38a 9.47b 0.007 ,0.001 ,0.001 NS
1 Data are mean and pooled SEM, n = 3 (pools of samples from 4 rats), expressed as log10 copy number/g of freeze-dried fecal sample. Within diet or time, means without a
common letter differ, P . 0.05. GOS, galacto-oligosaccharide; GOS-La, lactose-derived galacto-oligosaccharide; GOS-Lu, lactulose-derived galacto-oligosaccharide.
2 Significance main effects (diet and treatment time) were determined by General Linear Model by 2-way repeated-measures ANOVA.
3 NS, nonsignificant, P . 0.05.
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d 7 to 14 in the GOS-Lu and GOS-La groups but not in the
controls. At d 14, the SI was greater in the GOS-Lu group than in
the GOS-La group and the values in both were greater than in
controls. These data suggest that GOS-Lu exerted a stronger
prebiotic effect than GOS-La.
Discussion
It is generally accepted that the major beneficial effects of
prebiotic carbohydrates occur in the large intestine due to the
slow transit of the substrates to be fermented and their effects on
microbiota diversity, which plays an important role in host
health (32). Several studies have demonstrated a modulatory
effect of commercially available GOS-La on fecal microbiota of
healthy human volunteers (33–35), whereas others have not
shown a significant effect (15,36). Interestingly, the administra-
tion to human volunteers of a GOS-La mixture containing
mainly b (1/3) as well as b (1/4) and b (1/6) linkages
proved to have a better bifidogenic effect than a commercially
available GOS-La mixture consisting of GOS having b (1/4)
and b (1/6) linkages only (35). These dissimilarities on the
selective growth of bifidobacteria could be attributed to several
factors, including resistance to hydrolysis and/or fermentation
selectivity of dietary oligosaccharides.
Whereas most research interest on prebiotics has focused on
their role as modulators of intestinal microbiota, few efforts
have been made to study the small intestinal resistance of dietary
GOS, 1 of the 3 major criteria that determine prebiotic potential
(4,33). Indeed, the elevated complexity of such samples poses a
challenge in analytical chemistry that increases when biological
samples are evaluated (11). Even if there are suggestions that
GOS-La reach the large intestinal sections intact, several studies
have revealed their susceptibility to partial hydrolysis (4); in
addition, no data regarding the in vivo digestibility of GOS-Lu
were previously reported. In the present study, we demonstrated
that GOS-La and GOS-Lu are resistant to in vivo digestion to
different extents, with the former being much more susceptible
to hydrolysis (Tables 1 and 2). Di- and trisaccharides resistant to
digestion in the upper gastrointestinal tract were completely
fermented by intestinal microbiota, as none were found in fecal
samples (Supplemental Figs. 1 and 2).
GOS, either produced from lactose or lactulose, are com-
posed of a very complex mixture of carbohydrates, differing in
their linkage type, number, and order of monomers in the
oligosaccharide chain. GOS derived from lactose and lactulose
usually comprise oligomers with a terminal glucose or fructose,
respectively. According to our results, these structural differ-
ences seem to have a considerable impact on susceptibility to in
vivo gastrointestinal digestion and, as a result, their potential as
prebiotic carbohydrates. Thus, GOS-Lu trisaccharides were
more resistant to hydrolysis than those derived from GOS-La
(Tables 1 and 2). Several intestinal brush border enzymes are
able to catalyze the hydrolysis of glycosidic linkages, such as
amylases and sucrases; in addition, other glycolytic enzymes
such as isomaltases and b-glycosidases can also contribute to
the digestion of dietary carbohydrates (37). Considering the
structures present in GOS-La trisaccharides, it is likely that
b-glycosidases present in the brush border of the small intestine
hydrolyze glycosidic linkages between galactoses and glucoses.
In this study, we demonstrated the susceptibility to hydrolysis of
49-galactosyl-lactose [Gal-(1/4)-Gal-(1/4)-Glc] (peaks 16
and 18, Table 2), as previously reported in vitro by Ohtsuka
et al. (18). The susceptibility to hydrolysis of GOS-La having a
DP $3 was also confirmed by the presence of their derivative
disaccharides in ileal samples (Supplemental Fig. 2A); likewise,
the abundance of Gal-(1/6)-Glc and Gal-(1/2)-Glc disac-
charides in ileal samples pointed to the high resistance of these
glycosidic linkages to the extreme conditions of the upper
digestive tract (peaks 6–9, Table 1 and Supplemental Fig. 2A). In
addition, a partial and selective fermentation of GOS-La by the
small intestinal microbiota may also occur and could explain the
reported growth stimulation of probiotic bacteria in the ileum of
weaned piglets after administration of several prebiotic carbo-
hydrates, including GOS-La (38).
GOS-Lu disaccharides were highly resistant to the acidic
environment and enzymatic digestion in the upper digestive tract
(Table 1), exhibiting a superior resistance to hydrolysis com-
pared with GOS-Lu trisaccharides. A plausible explanation for
this differential behavior could be the role that both monomer
and linkage type may play in resisting the action of the digestive
enzymes (39). Thus, the higher digestibility of GOS-Lu trisac-
charides compared with disaccharides could be attributed to the
higher susceptibility to the action of hydrolytic enzymes of some
specific linkages between galactose residues, as observed for
those contained in the 49-galactosyl-lactose [Gal-(1/4)-Gal-
(1/4)-Glc], compared with those involved in the formation of
galactosyl-fructoses. In this context, lactulose is not hydrolyzed
or absorbed in the small intestine but selectively fermented by
the colonic microbiota (33,40). GOS-Lu disaccharides are
mostly composed of b-galactobioses and galactosyl-fructoses,
as previously reported by Hernandez-Hernandez et al. (11).
Therefore, in a similar way to lactulose, it is very plausible that
other galactosyl-fructoses, such as those contained in peaks 4,
5b, 8, 9, 10, 11b, 15, 16, and 18 (Table 1), are quite resistant to
digestion within the mammalian gastrointestinal system and
have the ability to reach the large intestine intact as fermentable
substrates for the resident intestinal microbiota.
In this study, we also evaluated the impact of GOS-La and
GOS-Lu, with significant differences in their major compo-
nents (Tables 1 and 2), on the fecal microbiota of growing rats.
Interestingly, the novel GOS-Lu exerted a stronger bifidogenic
effect on fecal microbiota than GOS-La, with the latter showing a
significant increase in lactobacilli population relative to the control
(Table 3). It has been suggested that variation in daily dose may
contribute to differences in the modulatory effect on intestinal
FIGURE 1 SI scores of fecal samples obtained from growing rats
fed a control, GOS-Lu, or GOS-La diet on d 7 and 14. Data are mean6
SD, n = 3 (pools of samples from 4 rats). Effects of diet (P = 0.004),
time (P = 0.001), and their interaction (P = 0.008) were significant.
Means at a time without a common letter differ, P , 0.05.
*Differences from corresponding d 7, P , 0.05. GOS-La, lactose-
derived galacto-oligosaccharide; GOS-Lu, lactulose-derived galacto-
oligosaccharide; SI, selectivity index.
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microbiota. GOS-La, administrated at doses of 5 g or higher,
was bifidogenic as observed in fecal samples of human healthy
volunteers, whereas a dose of 2.5 g had no significant effect
(41). These authors suggested that a minimum or threshold
dose may exist below which a bifidogenic effect is not observed.
Consequently, it seems likely that GOS having an extended
period of digestion in the upper digestive tract will have a
stronger dose-dependent effect on their ability to modulate the
intestinal microbiota, where higher doses are necessary for such
an effect. We suggest that the amounts of GOS that reach the
large intestine depend on their structural characteristics that,
therefore, may influence their potential prebiotic effects. Given
the differences in the digestive physiology between rat and
humans, the results obtained cannot automatically predict the
prebiotic responses in humans. Our data suggest that a detailed
chemical characterization and studies of digestibility using in
vivo model systems, in support of human intervention studies,
are relevant for dietary recommendations and help to determine
criteria for developing novel prebiotics.
In spite of rapid research advances in gut microbial ecology,
the systematic understanding of this complex ecosystem and its
microbial interactions are still limited. Our microbiological data
reflect the effects of GOS-Lu and GOS-La at a group level only.
Not all bifidobacteria are likely to be able to utilize or compete
for these prebiotics. Regarding this relevant area, further studies
are in progress to investigate which types or species of
bifidobacteria are selectively affected by these prebiotics in the
large intestine. Analyses of microbiota have shown the stimu-
lation on growth of not only bifidobacteria or lactobacilli but
also the E. rectale/C. coccoides group (Table 3). An increase in
the populations of E. rectale/C. coccoides has been reported in
human intervention studies after treatment with prebiotics (42).
These bacteria are known to produce relatively high amounts
of butyrate (43), which could exert a protective role in protec-
tion against inflammatory bowel disease and colorectal cancer
(44). Although its physiological relevance needs to be investi-
gated more deeply, some authors have claimed that the prebiotic
concept may be expanded toward other genera, including
Eubacterium and Roseburia (14).
In conclusion, GOS-La and novel GOS-Lu were incorporated
in a single dose (1%, wt:wt) to rats for a period of 14 d. Under
such conditions, these compounds have met the 3 main criteria
that a food ingredient must satisfy to be considered as prebiotic
(4,45): 1) show resistance, at least to some extent, to gastric
acidity, hydrolysis by mammalian enzymes, and gastrointestinal
absorption; 2) act as a substrate for fermentation by intestinal
microorganisms; and 3) show selective stimulation of the growth
of intestinal bacteria associated with health and well-being. Our
findings revealed that GOS-Lu had a higher resistance to in vivo
gastrointestinal digestion and absorption in the small intestine,
likely to be due to the presence of a fructose residue at the
reducing end of the oligosaccharides. The partial digestion of
GOS-La trisaccharides suggested that glycosidic linkages Gal-
(1/6)-Glc and Glc-(1/2)-Glc are more resistant to in vivo
gastrointestinal digestion than the linkage type Gal-(1/4)-Gal.
The absence of resistant GOS in fecal samples indicated that the
oligosaccharides served as fermentation substrates in the large
intestine. As a result, a stronger bifidogenic effect was observed
in fecal samples of rats fed GOS-Lu compared with those fed
GOS-La. Interestingly, a significant increase in the population of
the E. rectale/C. coccoides group was also revealed following
treatment with GOS-Lu or GOS-La. To the best of our knowl-
edge, this work provides the first evidence for the in vivo prebiotic
effects of GOS-Lu, indicating that these novel oligosaccharides
could have the ability to reach the large intestine in physiolog-
ically relevant doses due to their low digestibility. Further in vivo
studies addressing the effect of GOS-Lu on the selective growth
of the intestinal microbiota are underway currently.
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